Inserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe Labellisée Par la Ligue Nationale Contre le Cancer, Paris, France.
Department of Medical Oncology, Institut Curie, PSL Research University, Paris, France.
J Natl Cancer Inst. 2021 Jan 4;113(1):80-87. doi: 10.1093/jnci/djaa047.
Uveal melanoma (UM) arises from malignant transformation of melanocytes in the uveal tract of the eye. This rare tumor has a poor outcome with frequent chemo-resistant liver metastases. BAP1 is the only known predisposing gene for UM. UMs are generally characterized by low tumor mutation burden, but some UMs display a high level of CpG>TpG mutations associated with MBD4 inactivation. Here, we explored the incidence of germline MBD4 variants in a consecutive series of 1093 primary UM case patients and a series of 192 UM tumors with monosomy 3 (M3).
We performed MBD4 targeted sequencing on pooled germline (n = 1093) and tumor (n = 192) DNA samples of UM patients. MBD4 variants (n = 28) were validated by Sanger sequencing. We performed whole-exome sequencing on available tumor samples harboring MBD4 variants (n = 9). Variants of unknown pathogenicity were further functionally assessed.
We identified 8 deleterious MBD4 mutations in the consecutive UM series, a 9.15-fold (95% confidence interval = 4.24-fold to 19.73-fold) increased incidence compared with the general population (Fisher exact test, P = 2.00 × 10-5, 2-sided), and 4 additional deleterious MBD4 mutations in the M3 cohort, including 3 germline and 1 somatic mutations. Tumors carrying deleterious MBD4 mutations were all associated with high tumor mutation burden and a CpG>TpG hypermutator phenotype.
We demonstrate that MBD4 is a new predisposing gene for UM associated with hypermutated M3 tumors. The tumor spectrum of this predisposing condition will likely expand with the addition of MBD4 to diagnostic panels. Tumors arising in such a context should be recognized because they may respond to immunotherapy.
葡萄膜黑色素瘤(UM)源于眼葡萄膜管内的黑色素细胞恶变。这种罕见的肿瘤预后不良,常发生化疗耐药性肝转移。BAP1 是已知的唯一导致 UM 的易感基因。UM 通常具有低肿瘤突变负担的特征,但一些 UM 表现出高水平的与 MBD4 失活相关的 CpG>TpG 突变。在这里,我们在连续的 1093 例原发性 UM 病例患者系列和一系列 192 例单体型 3(M3)UM 肿瘤系列中,探讨了种系 MBD4 变体的发生率。
我们对 UM 患者的汇集种系(n=1093)和肿瘤(n=192)DNA 样本进行了 MBD4 靶向测序。通过 Sanger 测序验证 MBD4 变体(n=28)。我们对含有 MBD4 变体的可用肿瘤样本进行了全外显子组测序(n=9)。对未知致病性的变体进行了进一步的功能评估。
我们在连续的 UM 系列中发现了 8 种有害的 MBD4 突变,与一般人群相比,发病率增加了 9.15 倍(95%置信区间=4.24 倍至 19.73 倍)(Fisher 精确检验,P=2.00×10-5,双侧),在 M3 队列中还发现了另外 4 种有害的 MBD4 突变,包括 3 种种系和 1 种体细胞突变。携带有害 MBD4 突变的肿瘤均与高肿瘤突变负担和 CpG>TpG 超突变表型相关。
我们证明 MBD4 是一种与高突变 M3 肿瘤相关的新的 UM 易感基因。随着 MBD4 被添加到诊断面板中,这种易感条件的肿瘤谱可能会扩大。在这种情况下发生的肿瘤应被识别,因为它们可能对免疫疗法有反应。